Using a special device to lower eye pressure in glaucoma patients
Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
This study is testing a special device called the Nanodropper to see if it can lower eye pressure just as well as regular eye drops for people with glaucoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT05273385 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of the Nanodropper device in reducing intraocular pressure (IOP) in patients with glaucoma compared to standard eye drops. Participants aged 18 and older with stable open-angle glaucoma or ocular hypertension will be randomly assigned to use either the Nanodropper or standard eye drops. The primary goal is to demonstrate that the Nanodropper is non-inferior in lowering IOP. Follow-up assessments will occur at one month and three months after treatment initiation.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with stable open-angle glaucoma or ocular hypertension who are currently using prostaglandin analogue eye drops.
Not a fit: Patients with uncontrolled glaucoma, recent eye surgery, or those using non-prostaglandin IOP-lowering medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective and potentially easier method for glaucoma patients to manage their condition.
How similar studies have performed: Previous studies have shown that smaller eye drops can be as effective as larger ones, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 years old or older 2. Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) 3. Use of prostaglandin analogue (PGA) eye drop 4. Stable disease status (no visual field loss progression or increase in IOP-lowering medications in the last 6 months) Exclusion Criteria: 1. Uncontrolled glaucoma 2. Have had eye surgery (including laser procedures) within the past six months 3. Have a diagnosis of acute angle-closure glaucoma and/or other retinal diseases 4. Use of non-PGA class of IOP-lowering medication
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Julius Oatts, MD — University of California, San Francisco
- Study coordinator: Mari Costantini
- Email: Mari.Costantini@ucsf.edu
- Phone: 415-353-2289
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.